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THE ASSOCIATION BETWEEN AGE AND LONG TERM 
 
COSMETIC EFFECT OF TREATMENT WITH BOTULINUM TOXIN 
KELSEY COX 
ABSTRACT 
 Cosmetic treatment with botulinum toxin type A injections is the top non-surgical 
cosmetic procedure in the U.S. Many patients are beginning treatment at a younger age to 
prevent the development of facial wrinkles associated with aging. However, there is 
limited data to support the use of prophylactic botulinum toxin injections. Patients 
beginning treatment at a younger age have fewer wrinkles requiring fewer units to treat, 
which reduces the overall cost of treatment. Patients also maintain higher levels of self-
esteem by preventing or delaying the onset of facial wrinkles that can negatively impact 
their appearance. This study proposes that patients receiving botulinum toxin injections at 
a younger age (< 35) will have higher satisfaction with treatment outcomes. By 
demonstrating an association between starting age of injections and patient satisfaction, 
this study aims to provide merit for clinical trials studying the effectiveness of 
prophylactic botulinum toxin injections for cosmetic indications. 
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INTRODUCTION 
Background 
Imprinted facial lines are the permanent lines that develop on a face after years of 
repeated muscle contractions causing dermal and epidermal breakdown.1 These lines, 
specifically horizontal forehead lines and vertical glabella (“11’s”) make one appear 
aged, tired, or angry.2 Decreasing the intensity of these lines and preventing imprinting 
with botulinum toxin has become a common office procedure in the field of cosmetic 
medicine.  Many providers and patients endorse benefits of starting treatments with 
botulinum toxin before facial lines initially appear.  
Botulinum toxin is part of the cosmetic injectable class known as 
neuromodulators.  The toxin blocks the release of acetylcholine from presynaptic nerve 
terminals into the neuromuscular junction, thereby preventing muscle contraction.2 
Cosmetic treatment with botulinum toxin causes intentional, sub-acute paralysis of 
muscles responsible for the development of facial lines. The rationale behind facial line 
prevention with botulinum toxin is that if the muscles are unable to make repeated 
contractions, then the resulting lines will not form, leaving the patient free of the 
undesired appearance mentioned above.  
Statement of the Problem 
Currently, there is no substantial evidence supporting the benefits of wrinkle prophylaxis 
with botulinum toxin, but patients are asking the question of “When is too early to 
start?”1 The only research documenting an early initiation of BTA treatment was a 
retrospective twin study in 2006.2 While the twin that started in her 20s had fewer facial 
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lines after 13 years of consecutive treatments, the other twin only had two treatments four 
years apart in her 30s. It is unknown if the second would have equal results and 
satisfaction if she started later, but continued with consecutive treatments.  
Early treatment equates to higher costs and more office visits over one’s lifetime, 
but patients are beginning treatments earlier despite the lack of evidence demonstrating 
the cost-effectiveness of wrinkle prophylaxis with BTA. These patients are likely 
satisfied with their treatment as the number of BTA procedures continues to increase and 
remains the most popular non-invasive aesthetic treatment in the United States.3  
Multiple studies have demonstrated that satisfaction with BTA treatment is high, 
but none have looked at satisfaction rates based on starting age.4 It was noted in clinical 
trials that BTA injections were more effective and lasted longer in younger vs. older 
patients, which would likely lead to higher rates of satisfaction, but this has yet to be 
demonstrated.5 
Hypothesis 
If botulinum toxin treatments are received at a younger age (< 35), then there will higher 
patient satisfaction with treatment outcomes. 
Objectives and specific aims 
Many patients begin treatment with botulinum toxin at an early age for wrinkle 
prevention by initiating therapy before facial lines develop. This study proposes to further 
explore the association between age at initiation of cosmetic treatments with botulinum 
toxin and patient satisfaction with treatment outcomes. Improved satisfaction in the group 
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receiving treatments at an earlier age could implicate further studies regarding 
prophylactic botulinum toxin treatment. 
•   To determine the relationship between younger starting age (< 35) of botulinum 
toxin treatments, patient satisfaction rates, and treatment outcomes using the 
Facial Lines Treatment Satisfaction Questionnaire 
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REVIEW OF THE LITERATURE 
Overview 
The human face provides a universal method of communication as well as a expressing 
an individual’s health, emotion, and age.6 It also presents a level of physical 
attractiveness that has social implications impacting the individual’s well-being.7 As the 
face ages, bone atrophy and loss of skin elasticity accelerate the appearance of wrinkles 
formed by repetitive contractions of the face.8 Even though they are not pathologic, these 
wrinkles become permanent, even at rest, and may have a significant effect on a person’s 
communication, attractiveness, and self-esteem.7 Botulinum toxin type A (BTA) 
injections have the ability to alleviate these negative effects associated with facial aging. 
 Facial expression is an integral part of verbal and non-verbal communication. The 
lines associated with aging portray facial miscues that incorrectly signal an emotion that 
is not felt. A depressed and furrowed brow signals that the person is worried, angered, or 
displeased. Brow depression and sagging eyelids portrays drowsiness or exhaustion. 
Sagging and down-turned corners of the mouth create an appearance of sadness or 
displeasure. Just a single glabellar crease may be interpreted as anxiety or irritation. 
These features are observed at rest as the face ages and give’s the individual a negative 
expression at baseline (Figure 1).7  
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Figure 1. Miscues of the aging face. Subject is cheerful and happy, but face projects 
affect of being tired, angry, and sad.7 
The disconnect between the social interpretation of one’s facial expression and 
that person’s actual emotion can lead to a miscommunication. For example, a patient with 
this problem might be asked “Why are you angry?” or “Are you tired today?” when the 
patient feels pleasant and rested. This inability to accurately communicate feelings and 
intentions becomes frustrating for the individual and puts them at a higher risk for anxiety 
and depression.9 Many patient receive BTA injections not to increase their attractiveness, 
but to remove the lines that cause false negative expressions and prevent the social 
implications of facial expression miscommunication.10  
The perceived age of one’s face has a significant effect on the societal 
interpretation of its attractiveness. “Individuals perceived to be attractive receive 
preferential treatment in education, employment, medical care, legal proceedings, and 
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romantic encounters, that often result in their being happier, more successful, more 
socially adept, and more sexually fulfilled than others.”7 Youthful appearance in females 
is a sign of beauty in many cultures as it represents health and fertility.7 It also is 
associated with desirability, sexuality, and success, whereas aging can imply inadequacy 
and decrepitude.11,12 Individuals that maintain a more youthful appearance as they age 
tend to be healthier and live longer with a positive outlook on life.13 BTA injections 
eliminate wrinkles and returns patients to their more youthful appearance. Treatment with 
BTA is also used to increase facial symmetry, which is a standard of beauty across many 
cultures.7 
An individual’s attractiveness has an effect on their self-esteem and how the 
individual is perceived by others. An attractive person is likely to receive positive 
responses, which promotes positive self-image and psychological health. The person’s 
perceived emotional state also impacts their social interactions. A smile or pleasant 
expression is more likely to elicit a smile from another person. This positive response 
results in continued positive behavior and enhanced interpersonal relationships. BTA 
injections allow individuals to look their best, which enhances their self-esteem and gives 
them a more optimistic attitude about social interactions. BTA injections also give the 
patient a more relaxed baseline expression that elicits a more positive response from 
others. The attractive, youthful, and pleasant appearance from BTA treatment results in 
improved psychological well-being and social functioning for that leads to a better 
quality of life for the patient.7 
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Wrinkles that cause facial aging are produced through a combination of repetitive 
muscle contraction and dermal atrophy.  Rather than attaching to bone like most muscles, 
facial muscles have soft tissue attachments to skin through the superficial muscular 
aponeurotic system. Contracting these muscles causes the overlying skin to move and 
form dynamic wrinkles perpendicular to the direction of muscle contraction (Figure 2).14  
 
Figure 2. Musculature and wrinkles of the face14    
 Glabellar wrinkles, also known as “frown lines” and “11’s” (due to their  
appearance), are vertical lines between the eyebrows formed by the glabellar complex 
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depressor muscles.14 These muscles include the procerus, corrugator supercilii, and 
depressor supercilii and their contraction pulls the eyebrows inferiorly and medially.14 
Horizontal forehead lines are produced by the contraction of the frontalis muscle which 
moves the eyebrows superiorly.14 Crow’s feet are caused by contraction of the lateral 
orbicularis oculi moving the lateral eyebrow inferiorly (Figure 3).14 
 
 
Figure 3. Functional anatomy of the face.14 
 
 All individuals will develop both dynamic and static facial wrinkles over the course 
of their lifetime.  Dynamic wrinkles begin as early as childhood, while the onset of static 
wrinkles takes place in early to middle adulthood, depending on anatomy and skin 
quality. Facial wrinkle treatment includes microdermabrasions, chemical peels, laser 
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therapy, topical creams, topical retinoids, surgical correction, injectable dermal fillers, 
and botulinum toxin injections (Table 1). Avoidance of UV rays, application of 
sunscreen, and possibly the early injection of botulinum toxin can help delay the onset of 
static wrinkles. 
 
Table 1. Facial Wrinkle Treatment Options 
 
Microdermabrasion Superficial skin resurfacing technique using aluminum 
oxide crystals to partially ablate the skin15 
Chemical peel Chemical agents (alpha or beta-hydroxy acids, Jessner’s 
solution, trichloroacetic acid, and phenol-croton oil 
combination) are used to resurface skin at either 
superficial, medium, or deep level16 
Laser therapy Ablating the entire epidermis using CO2 or Er:YAG 
laser to resurface skin17 
Topical creams A variety of active ingredients (alpha-hydroxy acids, 
ascorbic acid, vitamin E, alpha lipoic acid, niacinamide, 
and N-acetyl-glucosamine)  promote youthful skin18 
Topical retinoids Retinol (vitamin A) derivatives, most commonly 
tretinoin, efface wrinkles by forming a repair zone of 
new collagen in the papillary dermis19 
Botulinum toxin injections Decreases wrinkles by temporarily paralyzing the 
muscles that are responsible for their formation 
Injectable dermal fillers Hyaluronic acid or other substances injected into the 
face to provide volume where collagen has degraded 
over time20 
Surgical correction Plastic surgeons perform rhytidectomies (face lifts) and 
other procedures to eliminate wrinkles and signs of 
aging of the face21 
 
 
 
 BTA was first identified in 1895 and isolated in the 1920s.22 Initially, BTA 
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treated only strabismus. However, it is now indicated for a variety of uses including 
cosmoses of facial lines, bladder dysfunction, chronic migraine, upper limb spasticity, 
cervical dystonia, primary axillary hyperhidrosis, and blepharospasm. Although it’s 
cosmetic use began in the 1980s, the first systematic study on its efficacy and safety was 
not published until 1992.22 To date, BTA is well-researched. There are numerous double-
blind, placebo-controlled studies showing BTA to have excellent efficacy and safety in 
the cosmetic treatment of glabellar, canthal, and chin rhytides.23 Currently, BTA is 
approved by the U.S. Food and Drug Administration for the cosmetic treatment of frown 
lines by the glabellar complex (2002) and crow’s feet by the orbicularis oculi muscles 
(2013).14 While it is widely used for lines in the upper one-third of the face, it is also used 
off-label to treat the lower two-thirds.14 
Botulinum toxin type A is one of eight serotypes of neurotoxin produced by the 
bacteria Clostridium botulinum.14 The toxin inhibits the release of acetylcholine from 
peripheral cholinergic and ganglionic nerve terminals; this causes paralysis by disrupting 
the neurotransmission required for muscle contraction.24 The molecular mechanism is 
well characterized. BTA cleaves synaptosomal-associated protein of 25 kDA (SNAP-25), 
a docking protein on the internal surface of neuronal membranes.24 This prevents vesicle 
fusion and the release of acetylcholine.14 SNAP-25 regenerates over time, allowing 
neuromuscular signaling and muscle contractility to eventually return.24  
There are currently three BTA preparations; onabotulinumtoxinA (Botox®), 
abobotulinumtoxinA (Dysport®), and incobotulinumtoxinA (Xeomin®).14 Complexing 
proteins surrounding the 150 kDa core botulinum neurotoxin vary depending on the 
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preparation.14 The preparations are not interchangeable due to their differences in dosing, 
formula, and clinical response.14 
Elective cosmetic treatment with botulinum toxin is not covered by insurance. 
The average units needed are 20 for the glabellar complex, 24 for forehead, and 12 per 
each set of crow’s feet. Treatment of forehead and glabella lines requires 40 units on 
average. Each unit is priced between $10-16, which amounts to $400-640 per treatment. 
The cost is compounded by the toxin’s half life. The paralysis effect of botulinum toxin 
lasts 3-6 months depending on the patient’s metabolism of the drug.25 Taken together, 
patients getting four treatments per year can spend up to $2,560 annually.   
Since treatments are not covered by insurance, expense is the main limiting factor 
when it comes to starting age and frequency of BTA injections.5 If patients wait too long 
and lines become imprinted, they would need to be treated with dermal fillers that are 
much more expensive per treatment than botulinum toxin.2 However, if lines have 
appeared, but have not become permanent, then botulinum toxin would be effective in 
reducing or eliminating these lines. Thus, botulinum toxin can be initiated as prevention 
or as treatment following initial appearance. To date, however, there are no studies 
showing the optimal time to initiate treatment from a cost-effectiveness standpoint. 
The prophylactic use of botulinum toxin to prevent facial line development and 
imprinting is demonstrated by a twin study published in JAMA Facial Plastic Surgery in 
2006.2 The first twin received botulinum toxin injections to the forehead and glabella 2-3 
times per year for 13 years while the second twin received just two treatments in her 30s.  
Results showed that “imprinted forehead and glabellar lines were not evident in the 
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regularly treated twin, but were evident in the minimally treated twin.”2 The authors 
concluded that “long-term treatment with botulinum toxin can prevent the development 
of imprinted facial lines that are visible at rest.”2 However, this study does not address 
the initiation of regular treatment soon after lines begin to form.  It is not known what the 
results would be if the minimally treated twin began regular botulinum toxin injections in 
her 30s instead of her two sporadic treatments. 
There are many documented benefits to botulinum toxin prophylaxis prior to the 
development of facial lines.  Cost per treatment is significantly less with prophylaxis than 
for treatment once lines develop. Additionally, some patients experience a longer period 
of effectiveness after consistent treatments.5 This further contributes to cost reduction. 
Patients with consistent treatments also benefit behaviorally. Patients with constant 
paralysis of facial muscles eventually learn to stop trying to contract these muscles for 
everyday facial expressions.25 The literature suggests this further prevents line 
development and may facilitate dermal remodeling.25  Lastly, there is no imprinting of 
lines thus there is no need for more expensive treatments with dermal fillers in the future. 
Disadvantages of therapy include long-term out of pocket expenses, early initiation of 
treatment (in the patient’s 20s), as well as the inconvenience of many years of regular 
office visits. 
 The use of BTA to treat the facial wrinkles associated with aging is steadily 
increasing. According to the American Society for Aesthetic Plastic Surgery, BTA 
treatment has been the most popular nonsurgical procedure since 2000.3 In 2014 alone, 
clinicians performed just under 3.6 million procedures. (Figure 4).  
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Figure 4: Top 5 Nonsurgical Procedures in 20143 
 
 BTA is administered as an intramuscular injection to facial muscles implicated in 
the development of wrinkles. An aesthetic consultation is first performed to determine the 
patient’s areas of concern and to discuss treatment options, expected results, and 
complications. The patient’s face is evaluated for asymmetries, such as uneven eyebrow 
height or eye aperture. Both dynamic and static photographs are taken before treatment to 
serve as comparisons for future visits. 
Setting realistic expectations for the results of treatment outcome is important 
during the consultation as therapeutic response varies.  Patients with only dynamic 
wrinkles typically demonstrate significant improvement with the first treatment (Figure 
5).14 These patients are using BTA prophylactically to prevent static line development. 
Patients with static lines at rest may require two to three consecutive treatments before 
any noticeable results (Figure 6).14 Deep static lines that have become imprinted are often 
refractory to BTA alone and require additional treatments, such as dermal fillers, in order 
to achieve desired results. Manually stretching the skin perpendicular to static lines can 
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indicate if they are imprinted. If the lines disappear with stretching, they are not 
imprinted and they will likely respond to BTA injections. The reverse also holds true; 
imprinted wrinkles could be refractory to BTA treatment and may require a dermal filler 
for cosmetic improvements.  
  
  
Figure 5. “Ideal candidate for botulinum toxin treatment demonstrating (A) 
dynamic frown lines with glabellar complex muscle contraction and (B) lack of 
static lines with glabellar muscles at rest.”14 Copyright © Rebecca Small, MD. 
   
Figure 6. “(A) Dynamic frown lines with glabellar complex muscle contraction and 
(B) static lines with glabellar muscles at rest.”14 Copyright © Rebecca Small, MD.  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There are several contraindications to cosmetic treatment with BTA injections. 
Physiologic contraindications include allergies to BTA product contents, neuromuscular 
disorders, and keloidal scarring. Relative social and psychiatric contraindications include 
unrealistic expectations, profession involving the use of facial expressions, and body 
dysmorphic disorder (Table 2).14 
 
Table 2. Contraindications to Botulinum Toxin Injection14 
Contraindications 
Sensitivity or allergy to constituents of the botulinum toxin product  
    (e.g., cow’s milk protein allergy with abobotulinumtoxinA)  
Neuromuscular disorder  
    (e.g., amyotrophic lateral sclerosis, myasthenia gravis, Lambert-Eaton 
syndrome,    myopathies)  
Gross motor weakness in the treatment area (e.g., Bell palsy)  
Dermatoses in the treatment area (e.g., psoriasis, eczema)  
Infection in the treatment area  
Pregnancy or breastfeeding  
Immunocompromised  
Keloidal scarring  
Body dysmorphic disorder  
Unrealistic expectations  
Dependency on facial expression for livelihood (e.g., actors, singers)  
 
 
BTA injections are performed on an outpatient basis and do not require 
anesthesia. Clinicians instruct patients to hold an ice pack on the injection site during 
BTA product preparation. After the skin is sterilized, the patient is asked to contract 
muscles (“frown,” “raise eyebrows,” “smile,” etc.) to show dynamic wrinkles and 
provide the clinician with better visualization of targeted injection sites. The clinician 
	  16 
then injects up to 1ml of solution using a 30-gauge, 1-inch needle.14 The glabellar 
complex is treated with injections into five sites: the midline of the procerus and 
bilaterally in the medial and midlateral corrugators (Figure 7).26 Crow’s feet are treated 
with three injection sites in the orbicularis oculi based on wrinkle location relative to the 
lateral canthis of the eye (Figure 8).26 Horizontal forehead lines are often treated by a 
series of injections 1-2cm apart across the medial forehead. After the injections are 
completed, patients are instructed to avoid certain activities to prevent unwanted spread 
of the toxin. Patients should avoid lying supine for four hours, massaging or heating the 
area, exercise, alcohol, and using hot tubs on the day of treatment.14  
 
 
 
Figure 7. Glabellar complex injection sites.26 
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Figure 8. Crow’s feet injection sites. 1) If lines are above and below the lateral 
canthus. 2) If lines are primarily below the lateral canthus.26 
 
 The effects of BTA injections can be seen as early as 3 days following treatment, 
while maximal results are seen around two weeks (Figure 9).14 Generally, the effects last 
three to four months, but they gradually diminish over that period. After multiple 
treatments, therapeutic effects may last longer for some patients, allowing extension of 
treatment intervals. 
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Figure 9. Dynamic frown lines with glabellar complex muscle contraction (A) before 
and (B) one month after onabotulinumtoxinA (Botox) treatment.14 Copyright © 
Rebecca Small, MD. 
  
There are a few complications associated with BTA injections. Burning or 
stinging at the injection site during the procedure is common and resolves within a few 
minutes. Additional complications are more rare, but include injection reactions and 
undesired BTA effects (Table 3).14 Injection reactions such as erythema, edema, 
tenderness, and headache usually resolve within a few days. Bruising can take up to a few 
weeks to resolve, but may be treated with ice or pressure to prevent worsening.  
Undesired effects of BTA are rare, but more distressing for patients. Most are due 
to BTA migration outside the treatment area. Migration causes paralysis of adjacent 
muscles not implicated in wrinkle formation. The incidence of these undesired effects 
declines with provider experience. Asymmetry and eyebrow ptosis can be caused by 
uneven dosing of BTA. Blepharoptosis, or upper eyelid droop, is due to “deep migration 
of botulinum toxin through the orbital septum fascia to the levator palpebrae superioris, 
an upper eyelid levator muscle” and can be prevented by keeping corrugator injections 
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1cm superior to the supraorbital ridge at the midpupillary line (Figure 10).14   
 
Table 3. Complications with Botulinum Toxin Injection14 
 
Injection Reactions Undesired Botulinum Toxin Effects 
Anxiety or vasovagal episode Allergic reaction 
Ecchymosis Antibodies against BTA 
Erythema, edema, and tenderness Blepharoptosis 
Headache Distant spread from injection site 
Infection Eyebrow ptosis 
Pain Facial asymmetry 
Paresthesia or dythesia Medication interactions 
 Undesired eyebrow shape 
 
 
 
 
 
Figure 10. “Right-sided blepharoptosis three weeks after botulinum toxin treatment 
of the glabellar complex for frown lines.”14 Copyright © Rebecca Small, MD. 
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Existing research 
The first study documenting the use of BTA injections for treatment of glabellar lines 
was published in 1992.27 While it demonstrated the efficacy and safety of treatment with 
BTA, the study only included 17 subjects and lacked a control group.27 Likewise, double-
blind, placebo-controlled studies in 1994 and 1996 showed significant safety and efficacy 
of BTA treatment, but included only 41 patients total.28,29 
 Carruthers et al (2002) was the first large scale double-blind, placebo-controlled, 
randomized, multi-center, clinical trial on the efficacy and safety of BTA injections for 
the treatment of glabellar lines.5 Two-hundred and sixty-four patients (203 BTA, 61 
placebo) received 20 unit injections to the glabellar complex muscles and followed-up at 
7, 30, 60, 90, and 120 days after the procedure. The study assessed physician-graded 
glabellar line severity, patient assessment of improvement, and adverse events.5 
 Results of this study demonstrated significant improvement of glabellar lines when 
compared to placebo. Physicians graded lines (0 = none, 1 = mild, 2 = moderate, 3 = 
severe) at baseline before treatment. At follow-up days 7, 30, and 60 the BTA group 
showed a mean improvement of 1.5 grades. At day 90 and 120, mean improvement in 
BTA group was 1.0 and 0.5 grades, respectively. Placebo group showed no improvement 
from baseline on any follow-up day. Patients used a 9-point scale (+4 = 100%, 0 = no 
improvement, -4 = 100% worse, each point = 25% change) to rate the improvement of 
their glabellar lines. The mean improvement scores of the BTA group were +3.0 at 30 
days, +2.7 at 60 days, +2.1 at 90 days, and +1.4 at 120 days. Mean improvement in the 
placebo group remained near zero at all follow-ups.5 
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 The adverse events observed were headache in 15% of patients in both groups and 
blepharoptosis in 5.4% BTA patients versus 0% in the placebo group. Most cases of 
headache and blepharoptosis were mild demonstrating that BTA is an overall safe 
procedure.5 
 The 2002 study was repeated in 2003 with the same measures and confirmed the 
results.25 In the follow-up study, 273 patients enrolled (202 BTA, 71 placebo). Physician-
rated mean improvement score for the BTA group was approximately 1.0 on days 7, 30, 
and 60, 0.75 on day 90, and 0.5 on day 120. The placebo group showed no improvement 
at any date. Patient-rated improvement in the BTA group was +3.0 at 30 days, +2.6 at 60 
days, +1.9 at 90 days, and +1.0 at 120 days. The placebo group showed little to no 
improvement at all follow-ups. Adverse events were also similar. Headache was reported 
in 11% of BTA patients and 20% placebo. Blepharoptosis was present in 1% of the BTA 
group and 0% of the placebo group.25 
 Now that the efficacy of BTA injections had been confirmed, Heckmann et al 
(2003) went a step further and showed the treatment’s impact on baseline expressions of 
the face.10 Forty volunteers first rated 102 incremental variations of 3 male and 3 female 
prototype faces. These faces were morphed by a computer program to display 0%, 25%, 
50%, 75%, and 100% of happiness, sadness, fear, or anger. One volunteer was unable to 
make this differentiation and was excluded from the data analysis. The others went on to 
rate the images of 20 patients before and 1 week after BTA injections.  
 Results indicated that BTA injections enhanced the patients baseline expression of 
happiness and decreased baseline expression of the other negative emotions. Happiness 
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was the least expressed emotion before treatment, but increased by 71% to become the 
most expressed emotion after treatment. Expression of sadness only decreased by 10%, 
but fear and anger decreased significantly, 49% and 40% respectively.10 These results 
indicate that BTA injections give patients a more pleasant expression at baseline, which 
will lead to more positive social interactions and eliminate the emotion-expression 
mismatch observed with facial aging.7 
 It is well-documented that patient satisfaction with BTA treatment is high, but 
methods of assessing satisfaction have been inconsistent between studies.30,31 Sommer et 
al (2003) used a general cosmetic dermatology assessment, not specifically for facial 
rhytides, while Foster et al (2007) used a non-standardized questionnaire. These studies 
achieved overall satisfaction rates of 80% and 90%, respectively.30,31  
 The development of the Facial Lines Treatment Satisfaction Questionnaire 
provided a standardized, validated, and reliable method of assessing patient satisfaction 
with BTA injections.32 Stotland et al (2007) used the Facial Lines Treatment Satisfaction 
Questionnaire to measure satisfaction regarding the results and procedure after BTA 
injections.4 In this study, 56 women with moderate to severe glabellar rhytides received 
20 units of BTA in the corregator and procerus muscles, and were evaluated 30 days and 
120 days after treatment. Patient were assessed in the following areas: investigator- and 
patient-rated global assessment of change in severity, patient self-perception of age, and 
patient satisfaction of the procedure and effects of treatment using the Facial Lines 
Treatment Satisfaction Questionnaire (Table 5 below).4 
 The results showed physicians and patients both reported significant improvement 
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in glabellar line severity at day 30 and day 120.4 Thirty-seven percent of patients 
perceived to look younger after treatment at day 30, while 34% believed so at day 120. 
Patients perceived that they looked a median of 5 years younger. None of the patients 
thought they looked older after receiving the BTA injections.4 
 Patient satisfaction was high. The overall satisfaction rates were 95% at day 30 and 
86% at day 120, and there was a mean total score of greater than or equal to five on the 
Facial Lines Treatment Satisfaction Questionnaire (Figure 11).4 Eighty-eight percent of 
patients at day 30 and 82% at day 120 reported satisfaction (i.e., greater than or equal to a 
score of 5) in the effects of treatment domain. Ninety-three percent of patients at day 30 
and 95% at day 120 reported satisfaction in the procedure experience domain. The 
majority of patients also reported satisfaction in the individual items in both domains of 
the Facial Lines Treatment Satisfaction Questionnaire (Figure 12).4 
 
Figure 11. Percent satisfaction in each domain and overall treatment of the Facial 
Lines Treatment Satisfaction Questionnaire4 
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Figure 12. Percent satisfaction in the Effects of Treatment Domain of the Facial 
Lines Treatment Satisfaction Questionnaire4 
 
 The use of the Facial Lines Treatment Satisfaction Questionnaire proved to be 
effective in assessing patient satisfaction with the BTA procedure and outcomes, but 
there were limitations to this study. The individual items on the questionnaire were not 
assessed at baseline before the procedure. Additionally, there is a major conflict of 
interest present in this study as Allergan Inc. provided the funding. This pharmaceutical 
company produces Botox, the most widely used brand of BTA. 
  There are no current studies demonstrating an association between age and effects 
of treatment with BTA. Many hypothesize that injections prior to the development of 
facial lines will prevent wrinkle formation by inhibiting repeated contraction of muscles 
implicated in their development. This theory makes sense from a biomechanics and 
physiologic standpoint, but there are downsides in practice. Most notably, earlier 
treatment equates to increased costs. Conversely, there is also the chance that upfront 
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spending on prophylactic treatment will result in reduced long-term costs, as more 
extreme forms of treatment will not be necessary. 
The only study comparing age and treatment outcomes with BTA is a twin study 
published in JAMA Facial Plastic Surgery in 2006.  The first twin received botulinum 
toxin injections to the forehead and glabella 2-3 times per year for 13 years.  The second 
twin received only 2 treatments, one at age 31 and one at age 35.  Photographs were 
taken of both twins (age 38) 4 months after the regularly treated twin’s last treatment.  
Results showed that “imprinted forehead and glabellar lines were not evident in the 
regularly treated twin, but were evident in the minimally treated twin”2 (Figure 13). The 
authors concluded, “long-term treatment with botulinum toxin can prevent the 
development of imprinted facial lines that are visible at rest.”2  
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Figure 13. The minimally treated twin (A, B, and C) and the regularly treated twin 
(D, E, and F). Hyperfunctional lines in the forehead (B and E) and glabellar regions 
(C and F) are visible in the minimally treated twin but not in the regularly treated 
twin.2 
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Although the results appear to show a dramatic difference between the twins, this 
study has many limitations. First, it does not address prophylactic treatment versus the 
initiation of regular treatment soon after lines begin to form. Second, this study is funded 
by Allergan, the maker of Botox –  this is a significant conflict of interest and reasonably 
questions the objectivity of the study. Third, the study is limited by its small sample size 
as results are not applicable to larger populations.  
  
	  28 
METHODS 
 
Study design 
The study design will be a retrospective study to determine if there is a correlation 
between starting age of BTA injections and patient satisfaction rates.  
Study population and sampling 
The study population will include dermatology patients from Boston Medical 
Center (BMC).  Patients eligible for the study are females between the ages of 40 and 50 
who received BTA injections for cosmetic treatment of facial wrinkles. Patients will be 
recruited by telephone and will be asked to complete the Facial Lines Treatment 
Satisfaction Questionnaire. If the patient completes the survey and does not meet 
exclusion criteria (Table 4), they will be included and their chart will be reviewed for age 
at initial treatment with BTA. 
A sample size of 500 patients, 250 patients per group, will be used in order to 
obtain a 10% difference in satisfaction rating between groups with a power of 0.80, type I 
error rate of 5%, and sampling ratio of 0.75.33 
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Table 4. Exclusion criteria4 
Received BTA injections at location other than BMC 
Received other facial rejuvenation treatments  
Undergone facial aesthetic surgery 
Had a significant facial movement disorder  
Preexisting brow or eyelid ptosis 
History of CVA, head injury, or other cerebral damage affecting the recognition or 
expression of emotion 
Had any psychiatric illness that might interfere with the ability to produce facial 
expressions or experience emotion normally 
Had any disorder or were using any agent that might interfere with neuromuscular 
function 
Keloidal scarring  
 
 
Study variables and measures 
The patients will be asked to rate their satisfaction using the validated Facial Lines 
Treatment Satisfaction Questionnaire (Table 5), in which patients rate their satisfaction 
on a seven-point scale (where 1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat 
dissatisfied, 4 = neutral, 5 = somewhat satisfied, 6 = satisfied, and 7 = very satisfied).4 
The mean score of all of the items will be calculated. Patients with a mean score of at 
least 5 will be considered to have achieved satisfaction.4  
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Table 5. Facial Lines Treatment Satisfaction Questionnaire32 
“Please rate your 
satisfaction in 
these areas.” 
Very 
dissatisfied 
Dissatisfied Somewhat 
dissatisfied 
Neutral Somewhat 
satisfied 
Satisfied Very 
Satisfied 
Overall 
satisfaction 
1 2 3 4 5 6 7 
Improvement 
of facial lines 
1 2 3 4 5 6 7 
Time to onset 1 2 3 4 5 6 7 
Improvement 
in appearance 
1 2 3 4 5 6 7 
Look relaxed 1 2 3 4 5 6 7 
Appear rested 1 2 3 4 5 6 7 
Look better 1 2 3 4 5 6 7 
Look younger 1 2 3 4 5 6 7 
Look like you 
feel 
1 2 3 4 5 6 7 
Confidence 1 2 3 4 5 6 7 
Competitive at 
work 
1 2 3 4 5 6 7 
 
 Patients that complete the Facial Lines Treatment Satisfaction Questionnaire will 
undergo a chart review to determine the age at which they began receiving BTA 
injections. Patients will then be split into two groups for further analysis. Patients who 
began BTA injections before age 35 will be compared to those who began injections at 
age 35 or older.  
Recruitment 
All female patients ages 40-50 who have received BTA injections as a cosmetic treatment 
at BMC will be recruited by telephone and asked to answer the eleven items on the 
effects of treatment domain of the Facial Lines Treatment Satisfaction Questionnaire. All 
patients fitting the criteria will be contacted to ensure enough agree to answer the 
questionnaire to obtain a sample size of at least 500.   
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Data collection 
The investigator will obtain the electronic medical record of all patients in the sample 
population. The investigator will locate the contact information in the chart and call the 
patient.  The investigator will conduct the telephone interview of the patient and record 
the responses. The investigator will then locate the record of the patient’s first BTA 
treatment and record the patient’s age at this time.   
Data analysis 
Data will be analyzed with a McNemar’s chi square test and logistic regression will be 
performed to measure strength of the associated odd’s ratio. Due to confounding 
variables such as age, frequency of treatment, and number of areas treated, cases and 
controls will be matched by age +/– 2 years, then matched logistic regression will be 
performed.  
 
 Timeline and resources 
The study will be conducted over the course of one year. The resources necessary include 
investigators to conduct the Facial Lines Treatment Satisfaction Questionnaire and at 
least one statistician to analyze the data collected.  Overall this study is cost-effective 
with labor being the greatest expense.  
 
Institutional Review Board 
The study will be submitted for review to the Boston University Medical Campus IRB for 
expedited review.  Expedited review is appropriate as this study is a phone questionnaire 
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and there is no clinical intervention being performed. This study is low-risk and patient 
confidentiality will be protected. Only investigators will have access to patient 
information. Patient identifiers will be removed before data is analyzed and published. 
Budget line items: Administrative Support  
•   Clerical (Wages)  
•   Data entry  
•   Statistical consulting  
  
	  33 
CONCLUSION 
Discussion 
The results of the study will determine if there is a correlation between younger 
starting age of BTA treatment and higher satisfaction rates. Satisfaction in this sub-group 
has not yet been studied and the sample size proposed is significantly larger than all of 
the previous research on BTA treatment satisfaction. This study is relatively cost 
effective (labor is the main expense) and it can be reproduced by any institution that 
offers cosmetic BTA treatment.  
This study is limited due to the subjective nature of the data from the Facial Lines 
Treatment Satisfaction Questionnaire.  The selection bias from the voluntary 
questionnaire will affect the data that is collected. The results are not likely to be 
generalizable because patients from only one medical center were included.  
Even if patients that begin BTA injections before 35 are more satisfied, it does not 
necessarily indicated that the long term treatment is more efficacious. A prospective 
clinical trial with objective data measures is needed to confirm if earlier initiation of BTA 
injections is superior. Higher satisfaction scores on the Facial Lines Treatment 
Satisfaction Questionnaire among patients who started treatments before 35 would justify 
this prospective study as patients with better results are more likely to be satisfied.    
Summary 
BTA injections are the most popular cosmetic treatment for the facial wrinkles associated 
with aging. Many patients are beginning treatments in their 20s before static facial lines 
develop as a means of prophylactic treatment and wrinkle prevention even though there is 
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no significant data supporting this concept. If this study demonstrates higher satisfaction 
rates in patients who begin BTA injections before age 35, then there is likely an 
association between early starting age and development of fewer facial wrinkles.  
All research on BTA treatment satisfaction demonstrated high satisfaction rates 
with the procedure and results. One of these studies even noted that results were superior 
on younger patients verses older patients, but research on starting age has not been 
conducted.5 The validated and reliable Facial Lines Treatment Satisfaction Questionnaire 
given to a large sample size of patients stratified by age would be a cost-effective method 
to provide evidence for allocating resources to future clinical trials.  
Clinical Significance 
As the average lifespan increases, patients no longer feel as old as they look and many 
are turning to cosmetic treatments such as BTA injections in order to bridge the aesthetic 
gap. Many patients are frustrated by facial aging changing their baseline expression to 
reflect an angrier, irritated, and tired appearance. An early start to BTA injections would 
prevent these facial changes keeping the patient’s baseline expression more pleasant. This 
leads to more positive social interacts for the patient. These enhanced interpersonal 
relationships as well as increased youthful attractiveness elevate the patient’s self-esteem. 
Although some oppose this procedure as it is for a cosmetic, not medical, indication, the 
confidence and improved communication gained as a result of early-initiated BTA 
injections significantly enrich quality of life for the patient. 
BTA is the most popular nonsurgical cosmetic procedure, but there is no data 
demonstrating an ideal age to begin treatment. Results of this study would provide merit 
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further research that would indicate the starting age that provides the patient with optimal 
treatment outcomes. Patients would then be able to obtain the most cost-effect treatment 
plan while avoiding the social and psychological consequences of the aging face.  
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